Citigroup
ANEB

Citigroup’s Anebulo Pharmaceuticals ANEB Stock Holding History

Citigroup’s Portfolio ANEB Stock Details ANEB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6
Closed -$15 – 6044
2025
Q3 		$15 Buy
+6
New +$14 ﹤0.01% 5916

Other funds holding ANEB

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup's ANEB Position: Q4 2025 in Review

Citigroup sold out of Anebulo Pharmaceuticals (ANEB) in Q4 2025, closing a stake of 6 shares — an estimated $15 sold.

Citigroup first reported a position in ANEB in Q3 2025 and held it in 1 quarter. The position peaked at $15 in Q3 2025. 19 funds tracked by Wall St. Rank hold ANEB as of Q4 2025.

  • Citigroup reported no remaining Anebulo Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 6 Anebulo Pharmaceuticals shares in Q4 2025, an estimated $15.
  • Citigroup first reported a position in Anebulo Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Citigroup's Anebulo Pharmaceuticals position peaked at $15 in Q3 2025.
  • 19 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.